ArticleCureus2026
Prevalence of Prosthetic Joint Infections in Patients With Haemophilic Arthropathy Treated at a Tertiary Hospital: A Retrospective Case-Control Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Haemophilia is an X-linked inherited bleeding disorder that predisposes patients to haemophilic arthropathy (HPA), which can lead to the need for total joint arthroplasty (TJA). One of the major complications associated with TJA in this cohort is prosthetic joint infection (PJI). This study evaluated the prevalence, clinical characteristics, and microbiological profiles of PJI in haemophilic patients undergoing TJA at the Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa. Methods A retrospective comparative case-control study was performed, reviewing 208 patients (105 with HPA and 103 non-HPA controls) who underwent TJA between January 1, 2003, and December 31, 2023. Clinical, demographic, and laboratory data were collected, and PJI prevalence, common pathogens, infection-free survival, and the influence of human immunodeficiency virus (HIV) were analysed. Results The overall PJI rate was 4% in both the HPA and non-HPA groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.